Quality of Life Impact in Patients with Cutaneous Toxicities Caused by Epidermal Growth Factor Receptor Inhibitors and Immunotherapy
Dermatology · 2024
DOI: 10.1159/000536332 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Dermatology, 2024. Verfasst von Maria Mannino und 7 weiteren Autor:innen. Beteiligte Einrichtung: U.O.C. di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy. Hauptthemen laut MEDLINE: Quality of Life, ErbB Receptors, Drug Eruptions, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
Background
Novel oncologic therapies, including epidermal growth factor receptor inhibitors (EGFR-Is) and immune checkpoint inhibitors (ICIs), are associated with a new spectrum of adverse reactions, with prominent cutaneous toxicities. The impact of cutaneous adverse events (cAEs) on patients’ quality of life (QoL) represents an unmet clinical need.
Objectives
The aims of this study were (1) to assess whether cutaneous toxicities directed therapies are effective in reducing the QoL burden via the submission of 2 patient reported outcome measures (PROMs); (2) to investigate whether class of oncologic therapy, type of cAE and toxicity severity differently impact on patients’ QoL.
Methods
A prospective observational study was conducted at the Dermatology department of the Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, from October 2018 to October 2019. Patients aged ≥18 years, under therapy with EGFR-Is or ICIs and experiencing a treatment-related cAE were eligible for the study. Dermatology Life Quality Index (DLQI) and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire – Core 30 version 3.0 (EORTC QLQ-C30) were administered to patients at first clinical visit (T0), at 1-month (T1), and at 3-month (T2) dermatological follow-up.
Results
Sixty cAEs of 51 patients have been recorded. A significant difference in the mean score for both DLQI and EORTC QLQ-C30 was found along the 3-months dermatological follow-up (p < 0.0001). A similar QoL improvement was reported for PROMs stratified by class of therapy and toxicity severity (p < 0.0001). No difference was reported for patients with pyogenic granuloma-like lesions and psoriasiform eruption as per DLQI. Class of therapy and toxicity severity did not differently impact on patients’ QoL at selected timepoints; we reported a higher EORTC QLQ-C30 score at T2 for patients developing psoriasiform eruption compared to other types of cAEs.
Conclusions
Early patients’ referral to dermatologists and tailored management could result in better QoL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- U.O.C. di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy.
- Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.
- Medical Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
- Medical Oncology, Università Cattolica del S. Cuore, Rome, Italy.
Zitieren
APA
Mannino, M., Sollena, P., Di Stefani, A., Rossi, E., D'Argento, E., Schinzari, G., Tortora, G., & Peris, K. (2024). Quality of Life Impact in Patients with Cutaneous Toxicities Caused by Epidermal Growth Factor Receptor Inhibitors and Immunotherapy. Dermatology. https://doi.org/10.1159/000536332
Vancouver
Mannino M, Sollena P, Di Stefani A, Rossi E, D'Argento E, Schinzari G, et al. Quality of Life Impact in Patients with Cutaneous Toxicities Caused by Epidermal Growth Factor Receptor Inhibitors and Immunotherapy. Dermatology. 2024. doi:10.1159/000536332
BibTeX
@article{Mannino2024,
author = {Mannino, Maria and Sollena, Pietro and Di Stefani, Alessandro and Rossi, Ernesto and D'Argento, Ettore and Schinzari, Giovanni and Tortora, Giampaolo and Peris, Ketty},
title = {Quality of Life Impact in Patients with Cutaneous Toxicities Caused by Epidermal Growth Factor Receptor Inhibitors and Immunotherapy},
journal = {Dermatology},
year = {2024},
doi = {10.1159/000536332}
}
EUVIMED